Agenus Current Ratio 2010-2022 | AGEN
Agenus current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Agenus Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$0.25B |
$0.17B |
1.45 |
| 2022-06-30 |
$0.29B |
$0.16B |
1.81 |
| 2022-03-31 |
$0.29B |
$0.16B |
1.78 |
| 2021-12-31 |
$0.33B |
$0.16B |
2.12 |
| 2021-09-30 |
$0.31B |
$0.15B |
2.05 |
| 2021-06-30 |
$0.09B |
$0.17B |
0.55 |
| 2021-03-31 |
$0.14B |
$0.14B |
0.98 |
| 2020-12-31 |
$0.11B |
$0.13B |
0.88 |
| 2020-09-30 |
$0.13B |
$0.15B |
0.85 |
| 2020-06-30 |
$0.11B |
$0.14B |
0.74 |
| 2020-03-31 |
$0.10B |
$0.13B |
0.81 |
| 2019-12-31 |
$0.09B |
$0.12B |
0.71 |
| 2019-09-30 |
$0.11B |
$0.13B |
0.81 |
| 2019-06-30 |
$0.14B |
$0.12B |
1.14 |
| 2019-03-31 |
$0.18B |
$0.11B |
1.70 |
| 2018-12-31 |
$0.08B |
$0.07B |
1.10 |
| 2018-09-30 |
$0.07B |
$0.06B |
1.16 |
| 2018-06-30 |
$0.07B |
$0.05B |
1.32 |
| 2018-03-31 |
$0.07B |
$0.03B |
2.16 |
| 2017-12-31 |
$0.07B |
$0.06B |
1.30 |
| 2017-09-30 |
$0.08B |
$0.05B |
1.55 |
| 2017-06-30 |
$0.11B |
$0.03B |
3.36 |
| 2017-03-31 |
$0.14B |
$0.04B |
3.80 |
| 2016-12-31 |
$0.09B |
$0.04B |
2.24 |
| 2016-09-30 |
$0.11B |
$0.04B |
3.14 |
| 2016-06-30 |
$0.14B |
$0.03B |
4.12 |
| 2016-03-31 |
$0.16B |
$0.03B |
5.17 |
| 2015-12-31 |
$0.18B |
$0.03B |
6.36 |
| 2015-09-30 |
$0.21B |
$0.03B |
7.39 |
| 2015-06-30 |
$0.15B |
$0.03B |
5.78 |
| 2015-03-31 |
$0.09B |
$0.02B |
4.06 |
| 2014-12-31 |
$0.04B |
$0.01B |
4.62 |
| 2014-09-30 |
$0.06B |
$0.02B |
3.54 |
| 2014-06-30 |
$0.07B |
$0.02B |
3.61 |
| 2014-03-31 |
$0.08B |
$0.01B |
5.24 |
| 2013-12-31 |
$0.03B |
$0.01B |
2.74 |
| 2013-09-30 |
$0.03B |
$0.01B |
3.20 |
| 2013-06-30 |
$0.01B |
$0.01B |
2.01 |
| 2013-03-31 |
$0.02B |
$0.01B |
3.18 |
| 2012-12-31 |
$0.02B |
$0.01B |
4.70 |
| 2012-09-30 |
$0.03B |
$0.01B |
5.34 |
| 2012-06-30 |
$0.03B |
$0.01B |
5.77 |
| 2012-03-31 |
$0.03B |
$0.01B |
4.71 |
| 2011-12-31 |
$0.01B |
$0.01B |
2.53 |
| 2011-09-30 |
$0.02B |
$0.01B |
2.73 |
| 2011-06-30 |
$0.01B |
$0.01B |
2.77 |
| 2011-03-31 |
$0.02B |
$0.01B |
3.03 |
| 2010-12-31 |
$0.02B |
$0.01B |
3.85 |
| 2010-09-30 |
$0.03B |
$0.04B |
0.64 |
| 2010-06-30 |
$0.03B |
$0.01B |
6.25 |
| 2010-03-31 |
$0.03B |
$0.01B |
4.57 |
| 2009-12-31 |
$0.03B |
$0.01B |
5.89 |
| 2009-09-30 |
$0.04B |
$0.01B |
5.81 |
| 2009-06-30 |
$0.02B |
$0.01B |
3.51 |
| 2009-03-31 |
$0.03B |
$0.01B |
4.36 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.783B |
$0.296B |
|
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
|
